Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Oncology 45

Oncology

recent-pharma-happenings-for-recursion-repertoire-cequr-eli-lilly

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, comprising pancreatic, colon, breast and salivary cancer, with 62.5% affected by gastrointestinal tumours. Across all 32 patients who administered Retevmo (selpercatinib), the researchers noticed a confirmed objective response rate (ORR) of 47%, with the median duration of response not yet reach with a follow-up of 13 months. As per Lilly, responses were ongoing in 73% of responding patients in the study. David Hyman, chief medical officer, oncology at Lilly, said that these en...

Explore More...

Cancer, diabetes and eczema on list; AbbVie’s Humira; Teva weighs $2B; Fresenius in buyout talks

Dengvaxia study; Opdivo racks up; FDA issues plant; Teva’s Rimsa fraud; Mission bags Fox grant

CRISPR finds faults in previous researches

Therapeutics

Valeant’s asset-sale; Sanofi coughs up $19.8M; Sanofi’s Genzyme; India’s Alkem; GSK’s inhalers

DNA typos to blame for most Cancer Mutations

Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings

AKT Inhibitors: A potential Cancer Immunotherapy Target

Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns

GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss

Colorectal Cancer Awareness Month

New biomarkers improve standard screening in Pancreatic Cancer

New biomarkers for screening in Pancreatic Cancer

Business Cocktail

NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Biocon win

Colorectal Cancer Market

Colorectal Cancer Market Analysis and Market Forecast

Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly